SavedAdd your journal

Journals / Turkish Journal of Veterinary and Animal Sciences / 2015 / Cilt: 39 - Sayı: 3

Effcacy of experimental inactivated and live Rhodococcus equi vaccines for thoroughbred Arabian mares in mice

Özgür ÖZDEMİR
Yasemin PINARKARA
Zafer SAYIN
Osman ERGANİŞ
Aslı SAKMANOĞLU
Hasan Hüseyin HADİMLİ
Pages
295–301
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was concluded that R. equi vaccines, and especially bacterin+VapA+IMS, areuseful to protect mice against R. equi infection.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to determine the effcacy of inactive Rhodococcus equi vaccine candidates included thatbacterin+aluminum hydroxide (Al(OH)3), bacterin+VapA+(Al(OH)3), bacterin+Montanide IMS 3012 (IMS), bacterin+VapA+IMS,and live vaccine using mice as a model.
📊
Key Findings & Data:Te efcacy of vaccine was evaluated according to clinical fndings, humoral and cellularimmunity (levels of INF-g and IL-4), and results of microbiological culture from internal organs in dead or sacrifced mice.
💡
Conclusion & Impact:It was concluded that R. equi vaccines, and especially bacterin+VapA+IMS, areuseful to protect mice against R. equi infection.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this study was to determine the effcacy of inactive Rhodococcus equi vaccine candidates included thatbacterin+aluminum hydroxide (Al(OH)3), bacterin+VapA+(Al(OH)3), bacterin+Montanide IMS 3012 (IMS), bacterin+VapA+IMS,and live vaccine using mice as a model. Te efcacy of vaccine was evaluated according to clinical fndings, humoral and cellularimmunity (levels of INF-g and IL-4), and results of microbiological culture from internal organs in dead or sacrifced mice. Inactive R.equi vaccines were subcutaneously administered to mice three times at 15-day intervals and live vaccine was intraperitoneally injectedonce. Fifeen days afer the last vaccination, aerosol challenges were carried out with the pathogenic R. equi VapA+K2002 strain in allgroups. Two mice were sacrifced from each challenge groups on days 1, 3, 5, and 7. The antibody titers of vaccinated mice were found tobe signifcantly higher than those of the controls. The largest number of INF-g positive samples were detected in the bacterin+VapA+IMSand bacterin+IMS groups. IL-4 positivity was determined only in live vaccine groups. The lowest reisolation rate of R. equi from internalorgans was observed in the bacterin+VapA+IMS group. It was concluded that R. equi vaccines, and especially bacterin+VapA+IMS, areuseful to protect mice against R. equi infection.

🔖

Cite This Article

ÖZDEMİR, Ö., PINARKARA, Y., SAYIN, Z., ERGANİŞ, O., SAKMANOĞLU, A., HADİMLİ, H. H. (2022). Effcacy of experimental inactivated and live Rhodococcus equi vaccines for thoroughbred Arabian mares in mice. Turkish Journal of Veterinary and Animal Sciences, Cilt: 39 - Sayı: 3, 295–301. https://ajindex.com/articles/615214

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Meijer WG, Prescott JF. Rhodococcus equi. Vet Res 2004; 35: 383–396
  2. Woolcock JB, Mutimer MD, Farmer AMT. Epidemiology of Corynebacterium equi in horses. Res Vet Sci 1980; 28: 87–90
  3. Muscatello G. Rhodococcus equi pneumonia in the foal. Part 1: Pathogenesis and epidemiology. Vet J 2012; 192: 20–26
  4. Takai S, Sekizaki T, Ozawa T, Sugawara T, Watanabe Y, Tsubaki S. Association between a large plasmid and 15- to 17-kilodalton antigens in virulent R. equi. Infect Immun 1991; 59: 4056–4060
  5. Pei Y, Nicholson V, Woods C, Prescott CF. Immunization by intrabronchial administration to 1-week-old foals of an unmarked double gene disruption strain of Rhodococcus equi strain 103+. Vet Microbiol 2007; 125: 100–110
  6. Cohen ND, Smith KE, Ficht TA, Takai S, Libal MC, Becu T, Leadon DP, Chafn MK, Martens RJ. Genetic variability among isolates of Rhodococcus equi obtained from horses and horse farms: Clinical implications. In: 49th Annual Convention of American Association of Equine Practitioners; New Orleans, LA, USA; 2003. pp. 385–390
  7. Ainsworth DM, Eicker SW, Yeagar AE, Sweeney CR, Viel L, Tesarowski D, Lavoie JP, Hofman A, Paradis MR, Reed SM et al. Associations between physical examination, laboratory, and radiographic fndings and outcome and subsequent racing performance of foals with Rhodococcus equi infection: 115 cases (1984-1992). J Am Med Assoc 1998; 213: 510–515
  8. Hurley JR, Begg AP. Failure of hyperimmune plasma to prevent pneumonia caused by Rhodococcus equi in foals. Aust Vet J 1995; 72: 418–420
  9. Becu T, Polledo G, Gaskin JM. Immunoprophylaxis of Rhodococcus equi pneumonia in foals. Vet Microbiol 1997; 56: 193–204
  10. Butler JE. Immunoglobulin diversity, B-cell and antibody repertoire development in large farm animals. OIE Revue Scientifque et Technique 1998; 17: 43–70
  11. Güler L, Gündüz K, Erganiş O, Durmaz M, Ok U, Gülcü Y. Rhodococcus equi pneumonia in foals: immunoprophylaxis, molecular and sero diagnostic studies. In: VI. National Congress of Veterinary Microbiology; Elazığ, Turkey; 2004 (in Turkish)
  12. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 2007; 25: 3752–3762
  13. Taouji S, Nomura I, Giguere S, Tomomitsu S, Kakuda T, Ganne V, Takai S. Immunogenicity of synthetic peptides representing linear B-cell epitopes of vapA of Rhodococcus equi. Vaccine 2004; 22: 1114–1123
  14. Cauchard J, Sevine C, Ballet JJ, Taouji S. Foal IgG and opsonizing anti-Rhodococcus equi antibodies afer immunization of pregnant mares